Skip to main content

Good value and good growth -- would you believe a smallcap Chinese biotech?

I was reviewing the BUY signals on the Ebb and Flow Report (available at the Alert HQ Premium free preview site) and came across a small cap Chinese company called China Biologic Products, Inc. (CBPO)

The fact that it was on the Ebb and Flow Report means that on the weekly chart the company seemed to be undergoing an upside reversal. The report also showed that the company's Price to Free Cash Flow and Cash Flow Yield were both attractive, it's PEG was a mere 0.2 and Price to Sales suggested the stock was somewhat of a bargain at the current price.

Here is the weekly chart upon which the Ebb and Flow Report BUY signal was based. You can see the bounce off the lower Bollinger Band which contributed to the signal.

Fundamentals --

Looking to dig deeper into the financials, I entered the symbol into the Trade-Radar Stock Inspector software and checked the Fundamental Analysis tab on the Dashboard. Every single LED was green except the one for Market Cap. At only $258 million, the diminutive market cap causes a yellow caution light to come on.

I very seldom see stocks that can light almost every single LED green. The significance is that it means the company shows value at the current price, is effectively managed, is undergoing growth, is not over-indebted and has good margins.

Here is a screen shot of the Dashboard (click to see a larger image):

Some of the standard valuation measures like PE, PEG, Price to Sales and Price to Book can be found on most financial web sites (and are all in value stock territory) so I'll just mention a few of the calculated values that are more unique to Trade-Radar Stock Inspector:
  • Annualized Free Cash Flow Yield - this is looking pretty good at nearly 20%. It is calculated based on most recent quarter FCF compared to market cap
  • Ratio of Enterprise Value to Free Cash Flow - the lower this ratio is the better value the stock can be considered. At only 5.9, this ratio is well within the value range
  • Enterprise Multiple - this is a commonly found measure on many sites and is a ratio of Enterprise Value/EBITDA. I have to draw your attention to this number because, at only 2.68, this measure suggests that China Biologics is way, way deep in value stock territory.
  • The company doesn't have much debt but another of the unique evaluations the software provides is the Cash Flow to Debt Coverage ratio and Survivability. Both of these values indicate the company is far from being over-extended in terms of debt.

Growth --

With respect to growth, the following chart from Google Finance shows how the last two quarters have shown rapid growth on both the top-line and bottom-line. Year-over-year growth and margins have improved as well.

This chart shows year-over-year revenue growth of 23% and quarterly earnings growth of 84%.

Background --

Some classify CBPO as a biotech but actually it is a biopharmaceutical company. As such, there is less risk of management having to rely on a scientific breakthrough to support the company. CBPO is focused on development, production, and manufacture of plasma-based pharmaceutical products in the People's Republic of China. They are the market leader there with sales that grew from $4 million in 2002 to $119 million in 2009. Interestingly, the company says that international competitors Baxter and CSL will have limited opportunities in China in the future as they only have permission to sell Human albumin products. CBPO sells Human Albumin, Human Immunoglobulin for Intravenous Injection, and various hyper-immune products with more products in the pipeline.

The blood plasma industry in China is still in the early development stages compared to western counterparts. According to an industry analyst, the growth rate will be 15% to 20% in the industry in China. The company hopes to grow faster than that.

Conclusion --

The fundamentals for China Biologics look quite solid. The Reuters site has a nice page where you can see how the company stacks up against the industry average and the S&P 500. For the most part, CBPO compares very favorably.

From a technical perspective, the stock looks ripe for a bounce. With our valuation measures looking so reasonable, there is no reason the stock couldn't run further. With the company reporting late in earnings season, however, there is a chance that the market will have peaked by then and will be taking all stocks down indiscriminately.

Despite how attractive the stock looks to me, investing in individual Chinese small cap stocks is not for the faint of heart. If you're interested in China Biologics, be aware of the risk that accounting standards may not be as robust in China as they are in the U.S. and that the Chinese government has the ability to materially impact the industry in which the company operates. Nevertheless, a small position for a patient investor looks like a reasonable bet.

Disclosure: long CBPO at time of writing


Popular posts from this blog

Running TradeRadar on Windows 7 and Windows 8

Development of the original TradeRadar Stock Inspector software was begun back in the days before Windows 7 and Windows 8 were available.

As these newer versions of Windows have become more popular, we have heard from some users that they are having problems installing and running TradeRadar on their newer PCs.

The good news is that TradeRadar will work just fine on Windows 7 and Windows 8. All you have to do is adjust the Windows Compatibility Settings to ensure TradeRadar runs as intended.

It is recommended that you can apply Compatibility Settings when running the initial installation; however, it is also possible to apply Compatibility Settings after the program has been installed.

Prior to installation
After downloading the install program, go to the folder where you have stored the TradeRadarStkInsp_7_Setup.exe or TradeRadarStkInsp_7_PRO_Setup.exe executable. Right-click on the executable file and select Properties. Click the Compatibility tab. Adjust the Compatibility mode to …

Durable Goods report for Sept just so-so but Computer segment is on fire

The Durable Goods advanced report for September 2011 was released on Wednesday.

I like to dig into the Durable Goods report because it can be useful for seeing how tech in aggregate is performing and how the sector may perform in the future. I always focus on two particular measures: shipments and new orders. Let's see how it played out last month.

Shipments -- 

I generally give less importance to Shipments since this is a backward looking measure reflecting orders that have been confirmed, manufactured and shipped. It's similar to earnings reports -- it's good to know but the data is in the past and we're more interested in the future. The following chart shows how September shipments looked for the overall tech sector:

Results for the overall tech sector were a bit weak but take a look at the next chart which tracks the Computers and related products segment:

Results here were actually quite good and, to make things even better, the previous month was revised upward.


Alert HQ has moved!

End of an era!

This site was started way back in 2006/2007 to showcase my blog posts and the Alert HQ buy signals and sell signals. Alert HQ grew to include other kinds of stock alerts including Swing Signals, Trend Busters, Trend Leaders, Cash Flow Kings and more.

In the meantime, I built a sister site, and I started using some of the same Alert HQ content over there. As a result, I am discontinuing the Alert HQ data here at

The good news, however, is that all the Alert HQ signals and stock screens are still completely free. In addition, the pages have been enhanced so that you can hover over a stock symbol and a small chart will pop up so you can get a quick look at the stock's recent price action. If you click on a symbol it will take you to a page with plenty of financial and technical analysis information (still free!) as well as a larger chart that you can play with in terms of adding or deleting indicators, moving averages, etc.

Click …